A Latina Woman With Relapsing-Remitting MS Planning to Have a Child
Neurology
Curriculum:
Tackling Challenging MS Case Scenarios: Evaluating Missed Opportunities to Improve Care
Tackling Challenging MS Case Scenarios: Evaluating Missed Opportunities to Improve Care
Credits:
0.25 AMA PRA Category 1 Credit(s) ™ 0.25 ANCC Contact Hours
0.25 AMA PRA Category 1 Credit(s) ™ 0.25 ANCC Contact Hours
Launch Date:
March 15, 2021
March 15, 2021
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
MS specialists, MS physician assistants, MS nurse practitioners and nurses, neurologists, neurology physician assistants, neurology nurse practitioners and nurses
Relevant Terms:
Multiple Sclerosis, MS
Mariko Kita, MD
Chief of Medicine
Virginia Mason Medical Center
Director, Neurology Clinical Trials
Benaroya Research Institute
Seattle, WA
Bio
Dr Mariko Kita received her bachelor’s degree in biology from Johns Hopkins University and her medical degree from Northwestern University School of Medicine. She completed her internship in internal medicine at Northwestern Memorial Hospital and her residency in neurology at the Hospital of the University of Pennsylvania. Dr Kita completed her fellowship in neuroimmunology at Mt. Zion Multiple Sclerosis Center, University of California School of Medicine. She joined Virginia Mason Medical Center and Benaroya Research Institute at Virginia Mason in 2000. Dr Kita is currently Chief of Medicine, Virginia Mason Medical Center; Director, Virginia Mason Multiple Sclerosis Center; and Director, Neurology Clinical Trials, Benaroya Research Institute.
Denise Bruen, ANP-BC, MSCN
University of Virginia
James Q. Miller Consultative MS Center
Charlottesville, VA
Bio
A Virginia native, Denise Bruen grew up in Reston, VA. She attended the University of Virginia for nursing and graduated in 1996. She then received her master’s degree in nursing from Rush University in Chicago, IL, in 2004.
Ms Bruen is an adult nurse practitioner and certified multiple sclerosis nurse. She specializes in caring for those living with MS. Ms Bruen has been a nurse practitioner at the University of Virginia since 2004 and has worked at the Multiple Sclerosis Clinic since 2010. She is the medical director for the Multiple Sclerosis Clinic and past president of the International Organization of Multiple Sclerosis Nurses.
| 1. | EVALUATE the impact of early initiation and long-term use of disease-modifying therapy (DMT) to reduce disability in patients with MS, including women of childbearing age | 2. | DESCRIBE clinical data relating to the use of biomarkers to aid in the recognition and assessment of disease progression in MS |
| 1. | EVALUATE the impact of early initiation and long-term use of disease-modifying therapy (DMT) to reduce disability in patients with MS, including women of childbearing age |
| 2. | DESCRIBE clinical data relating to the use of biomarkers to aid in the recognition and assessment of disease progression in MS |
SPONSORSHIP & SUPPORT
This educational activity is jointly provided by the American Academy of CME and Spire Learning.
This activity is supported by educational grants from Biogen Inc. and Novartis Pharmaceuticals Corporation.
PROGRAM OVERVIEW
Multiple sclerosis (MS) is a chronic neurodegenerative disease with a complex clinical course, and many health care professionals may miss opportunities to deliver evidence-based care. Join our expert faculty as they discuss patient scenarios to highlight methods to avoid missed opportunities for the care team to provide optimal care for patients with MS.
TARGET AUDIENCE
MS specialists, MS physician assistants, MS nurse practitioners and nurses, neurologists, neurology physician assistants, neurology nurse practitioners and nurses
LEARNING OBJECTIVES
Upon completion of this educational activity, learners should be better able to:
- EVALUATE the impact of early initiation and long-term use of disease-modifying therapy (DMT) to reduce disability in patients with MS, including women of childbearing age
- DESCRIBE clinical data relating to the use of biomarkers to aid in the recognition and assessment of disease progression in MS
ACCREDITATION AND CREDIT DESIGNATION
In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and Spire Learning. American Academy of CME, Inc., is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.Physicians: American Academy of CME, Inc., designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NPs/Nurses: American Academy of CME, Inc., designates this educational activity for 0.25 ANCC contact hours (0.1 pharmacotherapeutic contact hours).
PAs: Per the AAPA, PAs attending an educational activity that has been designated for AMA PRA Category 1 Credit™ may claim up to the maximum number of credits designated.
HOW TO RECEIVE CREDIT
To receive credit for your participation in this educational activity:
- Read the objectives and other introductory CME information
- Complete the preassessment prior to the start of the activity
- Participate in the MS case activity
- Complete the postassessment and evaluation at the conclusion of the activity
If you are seeking credit, you must complete the evaluation at the conclusion of the activity.
CONFLICT OF INTEREST STATEMENT
According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence.
PLANNING COMMITTEE CO-CHAIRS
Mariko Kita, MD
Chief of Medicine
Virginia Mason Medical Center
Director, Neurology Clinical Trials
Benaroya Research Institute
Seattle, WA
Disclosure Statement:
Advisory Board – for scientific information: Biogen Inc; EMD Serono
Promotional Speakers Bureau: Biogen Inc; EMD Serono
Denise Bruen, ANP-BC, MSCN
University of Virginia
James Q. Miller Consultative MS Center
Charlottesville, VA
Disclosure Statement:
Advisory Board – for marketing purposes: Biogen Inc; Genentech Inc; Life Sciences; Novartis Pharmaceuticals Corporation; Sanofi Genzyme
Advisory Board – for scientific information: Genentech Inc; Novartis Pharmaceuticals Corporation; Sanofi Genzyme
EDUCATIONAL PLANNING COMMITTEE
American Academy of CME, Inc.
John Juchniewicz, MCIS, CHCP, Natalie Kirkwood, RN, BSN, JD: No relevant financial relationships with any commercial interests.
Spire Learning
Mairead Early has nothing to disclose.
Jeanne Prater discloses the following:
Employee (spouse): Novo Nordisk Inc; Shareholder (spouse): Johnson & Johnson
Christopher Washburn, PhD, discloses the following:
Employee (spouse): Janssen Pharmaceuticals, Inc
Reviewer
Kathleen Costello, MS, ANP-BC, MSCN, MSCS: No relevant financial relationships with any commercial interests.
OFF-LABEL STATEMENT
The faculty does not discuss non–FDA-approved or investigational agents for the treatment of multiple sclerosis (MS).
DISCLAIMER
The opinions expressed in this educational activity are those of the faculty and do not represent those of the Academy or Spire Learning. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, consult appropriate resources for any product or device mentioned in this activity, and draw conclusions only after careful consideration of all available scientific information.
PRIVACY
For more information about the American Academy of CME privacy policy, please access https://www.academycme.org/privacy.htm
For more information about the American Academy of CME privacy policy, please access https://www.academycme.org/privacy.htm
Spire Learning Privacy Policy:
Spire Learning, LLC is committed to protecting the privacy of personal information from our participants and educational collaborators. Spire maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of personal information.
Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing an activity. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of each activity. All evaluative information submitted is collected and retained, and used by Spire Learning, LLC to continuously improve the learning experience.
Spire Learning, LLC will not transfer, sell, or share personal information with outside parties or otherwise disclose personal information unless required to in a legal process. Spire will retain your personal data only for the period necessary to accomplish the stated purposes and to comply with applicable laws.
COPYRIGHT INFORMATION
Copyright © 2021 by Spire Learning, LLC and its Licensors. All rights reserved. No part of this publication or activity may be reproduced or transmitted in any form, by any means, without prior written permission of Spire Learning, LLC. Spire Learning, LLC and the American Academy of CME will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication or activity, including any claims related to the products, drugs, or services mentioned herein.
Spire Learning, LLC is committed to protecting the privacy of personal information from our participants and educational collaborators. Spire maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse, or alteration of personal information.
Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing an activity. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of each activity. All evaluative information submitted is collected and retained, and used by Spire Learning, LLC to continuously improve the learning experience.
Spire Learning, LLC will not transfer, sell, or share personal information with outside parties or otherwise disclose personal information unless required to in a legal process. Spire will retain your personal data only for the period necessary to accomplish the stated purposes and to comply with applicable laws.
COPYRIGHT INFORMATION
Copyright © 2021 by Spire Learning, LLC and its Licensors. All rights reserved. No part of this publication or activity may be reproduced or transmitted in any form, by any means, without prior written permission of Spire Learning, LLC. Spire Learning, LLC and the American Academy of CME will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication or activity, including any claims related to the products, drugs, or services mentioned herein.
CONTACT
For any questions, please contact: CEServices@academycme.org
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Microsoft Edge Google Chrome 60 or higher Mozilla Firefox 60 or higher Apple Safari 11.0 or higher For video, install the latest version of Quicktime. | Supported Phones & Tablets: iOS 9.3 and higher Android 7.0 (Nougat or higher) Microsoft Windows 8 Chrome OS |
| Additional Recommendations and Requirements | |
| Display Resolution & Color Depth | Resolution - 960 X 768 minimum - 1024 X 768 recommended min. Color Depth - 8 bits (256 colors) minimum - 16 bits (High colors) minimum |
| Audio | - Microphone - Speakers or headphones - Audio recording support |
| Word Processing | Software that can open, modify, and save documents in Rich Text Format (RTF). Microsoft Word and PowerPoint are recommended. |
